Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy - PubMed (original) (raw)

. 2023 Mar 21;81(11):1035-1045.

doi: 10.1016/j.jacc.2023.01.012.

Mark Tatangelo 2, Sachin Ahuja 3, Chun-Po Steve Fan 2, Sandar Min 4, Myriam Lafreniere-Roula 5, Tanya Papaz 6, Vivian Zhou 4, Kathryn Armstrong 7, Peter F Aziz 8, Lee N Benson 1, Ryan Butts 9, Andreea Dragulescu 1, Letizia Gardin 10, Justin Godown 11, Aamir Jeewa 1, Paul F Kantor 12, Beth D Kaufman 13, Ashwin K Lal 14, John J Parent 15, Marc Richmond 16, Mark W Russell 17, Seshadri Balaji 18, Elizabeth A Stephenson 1, Chet Villa 19, John L Jefferies 20, Robert Whitehill 21, Jennifer Conway 22, Taylor S Howard 23, Stephanie J Nakano 24, Joseph Rossano 25, Robert G Weintraub 26, Seema Mital 27

Affiliations

Free article

Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy

Aine Lynch et al. J Am Coll Cardiol. 2023.

Free article

Abstract

Background: Genetic defects in the RAS/mitogen-activated protein kinase pathway are an important cause of hypertrophic cardiomyopathy (RAS-HCM). Unlike primary HCM (P-HCM), the risk of sudden cardiac death (SCD) and long-term survival in RAS-HCM are poorly understood.

Objectives: The study's objective was to compare transplant-free survival, incidence of SCD, and implantable cardioverter-defibrillator (ICD) use between RAS-HCM and P-HCM patients.

Methods: In an international, 21-center cohort study, we analyzed phenotype-positive pediatric RAS-HCM (n = 188) and P-HCM (n = 567) patients. The between-group differences in cumulative incidence of all outcomes from first evaluation were compared using Gray's tests, and age-related hazard of all-cause mortality was determined.

Results: RAS-HCM patients had a lower median age at diagnosis compared to P-HCM (0.9 years [IQR: 0.2-5.0 years] vs 9.8 years [IQR: 2.0-13.9 years], respectively) (P < 0.001). The 10-year cumulative incidence of SCD from first evaluation was not different between RAS-HCM and P-HCM (4.7% vs 4.2%, respectively; P = 0.59). The 10-year cumulative incidence of nonarrhythmic deaths or transplant was higher in RAS-HCM compared with P-HCM (11.0% vs 5.4%, respectively; P = 0.011). The 10-year cumulative incidence of ICD insertions, however, was 5-fold lower in RAS-HCM compared with P-HCM (6.9% vs 36.6%; P < 0.001). Nonarrhythmic deaths occurred primarily in infancy and SCD primarily in adolescence.

Conclusions: RAS-HCM was associated with a higher incidence of nonarrhythmic death or transplant but similar incidence of SCD as P-HCM. However, ICDs were used less frequently in RAS-HCM compared to P-HCM. In addition to monitoring for heart failure and timely consideration of advanced heart failure therapies, better risk stratification is needed to guide ICD practices in RAS-HCM.

Keywords: Noonan syndrome; RASopathy; hypertrophic cardiomyopathy; implantable cardioverter-defibrillator; pediatric; sudden cardiac death.

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The project was supported through funding from the Ted Rogers Centre for Heart Research, the Heart and Stroke Foundation/Robert M Freedom Chair, and the Canadian Institutes of Health Research to Dr Mital. Dr Lynch is supported by a Heart Failure Research Fellowship from Bristol Myers Squibb, Mitacs, and Myant. Dr Mital has served as a consultant for Bristol Myers Squibb and Tenaya Therapeutics; and has received unrestricted education funding from Bristol Myers Squibb. Dr Conway has served as a medical monitor for the PumpKIN trial; and has received unrestricted education funding from Abbott. Dr Rossano has served as a consultant for Merck, Bayer, Myokardia, and Cytokinetics. Dr Kantor has served as a consultant for Novartis and AstraZeneca. Dr Balaji has served as a consultant for Milestone Pharmaceuticals and Janssen Pharmaceuticals; and has received a research support grant from the Medtronic External Research Program. Dr Godown has served as a consultant for Daiichi-Sankyo. Dr Aziz has served on the Medical Advisory Board for Medtronic. Dr Jeewa has served as a medical monitor for the PumpKIN trial; and has served as a consultant for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Comment in

Publication types

MeSH terms

LinkOut - more resources